TACSTD2 and neoplasm: Importantly, in all experiments with TROP2-negative tumor cells admixed with TROP2-overexpressing cells, Dato-DXd induced significantly higher killing when compared with the CTL-ADC, confirming the specificity of the ADC against TROP2-positive targets.